The rate of opioid abuse and dependence in the United States has increased over the last several years.1-3 From 1995 to 2002, emergency department visits related to heroin use increased by 22%, while visits related to prescription opioid pain medications increased even more, by up to 560% for oxycodone.3 While a proportion of these latter visits may have been appropriate visits related to pain control, it is likely that some proportion of these visits were due to opioid addiction and abuse. Because of this recent trend, access to substance abuse treatment programs that provide pharmacologic opiate replacement therapy is important.

Maintenance pharmacotherapy with an opioid agonist medication such as methadone can significantly reduce the adverse consequences of chronic opioid dependency,4-10 yet fewer than 20% of opioid-dependent individuals are enrolled in programs that provide such treatment.11,12 Many issues contribute to the low use of opioid addiction treatment programs, including insufficient capacity of programs to enroll patients, absence of programs in some geographic locations, and patient reluctance to enter stigmatized and regulated programs.

To improve access to pharmacotherapy for opioid dependence, the federal Drug Addiction Treatment Act of 2000 (DATA 2000) and the US Food and Drug Administration (FDA) approved buprenorphine for opioid addiction treatment. This act enables physicians to prescribe buprenorphine, a sublingual long-acting partial opioid agonist, for treatment of opioid dependency outside of traditional substance abuse treatment program settings.

Currently, patients can receive opioid addiction treatment with buprenorphine from primary care doc-
tors, a practice that has been shown to be safe and feasible.\textsuperscript{11,13-17} However, the availability of buprenor-
phine remains limited. To our knowledge, no studies have been published that examine primary care physi-
cians’ attitudes and beliefs regarding substance abuse treatment with buprenorphine in outpatient primary

care practice. Thus, little is known about whether such attitudes might explain the limited acceptance of
buprenorphine treatment in outpatient settings. This study’s objective was to assess attitudes and beliefs of
primary care providers in the Bronx, NY, about opioid addiction treatment with buprenorphine.

Methods

Design and Participants

We conducted a cross-sectional study with face-to-

face interviews involving resident and attending physi-
cians from six different ambulatory clinics associated
with a university teaching hospital in the Bronx, NY.
The resident physicians were from family medicine,

internal medicine preliminary, categorical, primary
care, and social medicine programs. Attending physi-
cians were family physicians and general internists.
Physicians were categorized as having affiliations with
primary care or non-primary care programs. Primary
care-oriented programs included the family medicine,

internal medicine primary care, and social medicine
programs. The non-primary care-oriented programs
included the internal medicine preliminary and cat-

ergorical programs.

The six clinics were chosen because of their diverse
settings, in which primary care was practiced. Five

clinics were community health centers (three with

only family physicians, one with only general intern-

ists, and one with general internists, pediatricians,

and obstetrician-gynecologists), and one clinic was a

hospital-based clinic with only general internists.
The resident physicians working within these clinics were
affiliated with both primary care and non-primary care
programs. Additionally, the patient populations

served by these clinics varied, with each clinic caring
for different groups of individuals, including working
people with private insurance, the working poor without
insurance, urban poor insured by Medicaid, and home-

less individuals.

Questionnaire

A research assistant administered questionnaires
from June 2003 to March 2005 using an adapted sur-
v

vey instrument.\textsuperscript{18} The original questionnaire was used
to assess attitudes and beliefs about opioid addiction
treatment with methadone in primary care providers.
Modifications to the questionnaire were made to accom-
modate the use of buprenorphine rather than methadone.
In an attempt to interview the physicians practicing in
each clinic, the interviewer was present on different
days of the week at different times of day. Specific days
and times were targeted to reach the largest number of
physicians present at one time. Gender, race, ethnicity,

training level, attitudes, and beliefs about opioid

addiction treatment options including buprenorphine
were elicited during the structured interview. Informed

consent was obtained from all participants, and the

study was approved by the Montefiore Medical Center
Institutional Review Board.

Analysis

We conducted descriptive analyses of providers’
attitudes and beliefs and factors related to them. We

report on the main factors examined—whether level

of training (resident versus attending), current opioid-
dependent patient panel size (currently treating

zero–four opioid-dependent patients versus five or

more), and training orientation (primary care versus

non-primary care) were associated with positive atti-
dudes toward treating substance users and prescribing

buprenorphine. Relationships between physicians’ atti-
dudes and beliefs about buprenorphine and the variables
of interest (listed above), as well as other demographic
characteristics, are also reported. The statistical sig-
nificance of differences in attitudes by these variables
was assessed using chi-square tests.

Results

Our sample was a convenience sample of 99 physi-
cians that included the physicians who were seeing

patients on interview days. All physicians who were

present in clinics on interview days agreed to par-

ticipate in the study. The majority were female, white,

non-Hispanic, and residents (Table 1). Most respondents

were from internal medicine primary care/social medi-
cine programs (53.5%).

Overall, 82.8% of respondents reported caring for

patients who use heroin or misuse prescription opioids.
However, only 73.7% were comfortable discussing il-
licit drug use with their patients, and just 51.5% were

comfortable discussing drug treatment. Many respon-
dents reported caring for substance users by referring

the patient to social workers, counselors, or substance
abuse treatment programs (62.6%).

Most respondents (84.7%) were aware of buprenor-
phine as a treatment option for opioid dependence.
However, only 37.8% believed that primary care provid-
ers should prescribe buprenorphine, and 56.1% were

unsure. While only 35.7% reported interest in prescrib-

ing buprenorphine, 72.1% were willing to prescribe it
to opioid-dependent patients if they had proper training
and support. The most common training/support needs

that were identified were education and training spe-
cific to buprenorphine (83.8%), available consultation
or case conferences (19.2%), and on-site counselors
or social workers (18.2%). The most-frequently stated
reasons for not prescribing buprenorphine were lack of knowledge or training (47.5%), lack of time (25.3%), the belief that treating opioid dependence is not a primary care issue (14.1%), and the lack of available supportive structures or services (13.1%).

In response to questions exploring factors associated with positive attitudes and beliefs around buprenorphine, physicians involved in primary care-oriented programs were more likely than those involved in non-primary care programs to believe that primary care providers should prescribe buprenorphine (47.3% versus 8.3%, $P<.05$), report interest in prescribing buprenorphine (43.2% versus 12.5%, $P<.05$), and report willingness to prescribe buprenorphine given the proper training and support (81.3% versus 45.5%, $P<.05$) (Table 2). Physicians who reported “lack of time” as a reason for not prescribing buprenorphine were less likely to report that primary care providers should prescribe buprenorphine (16.0% versus 45.2%, $P<.05$) and less likely to report willingness to prescribe buprenorphine (50.0% versus 80.7%, $P<.05$) than those who did not report lack of time as a reason to not prescribe buprenorphine. Finally, women were more likely than men to report interest in prescribing buprenorphine (44.3% versus 19.4%, $P<.05$).

**Discussion**

In this study of urban primary care providers, most physicians reported treating patients who use heroin or misuse opioids and were aware of buprenorphine as a treatment option. Just over one third of physicians reported that primary care providers “should” prescribe buprenorphine and reported “interest” in prescribing buprenorphine themselves. A total of 72% of physicians reported “willingness” to prescribe buprenorphine if they received proper training and support, underscoring the need for proper training and support. The data suggest that physicians associated with primary care-oriented programs were more likely to report interest and willingness to prescribe buprenorphine than those associated with non-primary care-oriented programs.

Few studies have examined health care providers’ attitudes regarding pharmacotherapy for opioid dependence outside of the traditional substance abuse treatment setting. Similar to our findings, McNeely and colleagues found that 66% of New York City physicians would prescribe methadone if given proper training and support. A recent study by Turner and colleagues revealed that 60% of directors of primary care and HIV clinics were willing to provide treatment with buprenorphine. One study focusing on pharmacists and pharmacy technicians found that they had positive attitudes regarding treating patients with buprenorphine, with 70% reporting willingness to participate in opioid addiction treatment with buprenorphine. However, another study reported that 81% of psychiatrists were not comfortable with office-based opiate agonist treatment and that factors associated with discomfort included female gender, lack of addiction certification, and little experience in treating addiction. While this is inconsistent with our findings, the distribution of these characteristics in our sample did not allow us to explore this fully. Future studies with larger samples of primary care physicians are needed to better understand these factors.

**Limitations**

Limitations of this study include the possibility that the results cannot be generalized given that the physicians were all recruited from one medical center in an urban teaching hospital in New York City. There may be differences in findings depending on structures of other health care systems, geographic regions, non-urban settings, or non-inner city patient populations.

Although the questionnaire for this study was a modified version of a questionnaire used in a previously published study, it has not undergone reliability and validation testing. Additionally, the relatively modest sample size limited our ability to identify factors that

---

Table 1

Physicians’ Characteristics and Attitudes, Beliefs, and Experiences With Substance Abuse Treatment in the Primary Care Setting

<table>
<thead>
<tr>
<th>Demographic Characteristic</th>
<th>Total n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean years, range: 24 to 54)</td>
<td>31.6</td>
</tr>
<tr>
<td>Male</td>
<td>37 (37.8)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>53 (53.5)</td>
</tr>
<tr>
<td>Black</td>
<td>9 (9.1)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>21 (21.2)</td>
</tr>
<tr>
<td>Other</td>
<td>16 (16.2)</td>
</tr>
<tr>
<td>Level of training*</td>
<td></td>
</tr>
<tr>
<td>Resident</td>
<td>78 (80.4)</td>
</tr>
<tr>
<td>Attending</td>
<td>19 (19.6)</td>
</tr>
<tr>
<td>Specialty/training program</td>
<td></td>
</tr>
<tr>
<td>Family medicine</td>
<td>22 (22.2)</td>
</tr>
<tr>
<td>Internal medicine, primary care or social medicine</td>
<td>53 (53.5)</td>
</tr>
<tr>
<td>Internal medicine, categorical or preliminary</td>
<td>24 (24.2)</td>
</tr>
</tbody>
</table>

*Two data points were missing for this variable.
may be independently associated with interest or willingness to prescribe buprenorphine.

**Conclusions**

Opioid addiction treatment with buprenorphine is not yet widely implemented in primary care settings across the United States, and understanding what supports are necessary to encourage its integration with other primary care services is important. This study indicates that for our sample of Bronx physicians, education and training specific to buprenorphine, available consultation or case conferences, and on-site counselors or social workers are necessary elements to providing opioid addiction treatment in the primary care setting. Common reasons that were reported for not prescribing buprenorphine included lack of knowledge and training, lack of time, lack of supportive services or structure, and the belief that prescribing buprenorphine is not a primary care issue. Addressing these training and support needs and barriers to prescribing buprenorphine are necessary in the development of programs to treat opioid dependence in the primary care setting.

---

**Table 2**

Factors Associated With Physicians’ Attitudes and Beliefs About Buprenorphine*

<table>
<thead>
<tr>
<th></th>
<th>Primary Care Providers Should Prescribe Buprenorphine</th>
<th>Interested in Prescribing Buprenorphine</th>
<th>Willing to Prescribe Buprenorphine With Training and Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>21 (34.4)</td>
<td>27 (44.3)**</td>
<td>41 (71.9)</td>
</tr>
<tr>
<td>Male</td>
<td>15 (41.7)</td>
<td>7 (19.4)</td>
<td>20 (71.4)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black/Hispanic/other</td>
<td>15 (33.3)</td>
<td>16 (35.6)</td>
<td>27 (64.3)</td>
</tr>
<tr>
<td>White</td>
<td>22 (41.5)</td>
<td>19 (35.9)</td>
<td>35 (79.6)</td>
</tr>
<tr>
<td>Level of training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attending</td>
<td>8 (42.1)</td>
<td>5 (26.3)</td>
<td>12 (70.6)</td>
</tr>
<tr>
<td>Resident</td>
<td>28 (36.4)</td>
<td>29 (37.7)</td>
<td>49 (73.1)</td>
</tr>
<tr>
<td>Training orientation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary care</td>
<td>35 (47.3)**</td>
<td>32 (43.2)**</td>
<td>52 (81.3)**</td>
</tr>
<tr>
<td>Non-primary care</td>
<td>2 (8.3)</td>
<td>3 (12.5)</td>
<td>10 (45.5)</td>
</tr>
<tr>
<td>Current panel of patients misusing opioids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;5 patients</td>
<td>14 (51.9)</td>
<td>11 (40.7)</td>
<td>21 (87.5)</td>
</tr>
<tr>
<td>0–4 patients</td>
<td>16 (33.3)</td>
<td>14 (29.2)</td>
<td>30 (71.4)</td>
</tr>
<tr>
<td>Reason for not prescribing buprenorphine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lack of time</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4 (16.0)**</td>
<td>5 (20.0)</td>
<td>12 (50.0)**</td>
</tr>
<tr>
<td>No</td>
<td>33 (45.2)</td>
<td>30 (41.1)</td>
<td>50 (80.7)</td>
</tr>
<tr>
<td>Lack of knowledge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21 (45.7)</td>
<td>16 (34.8)</td>
<td>32 (78.1)</td>
</tr>
<tr>
<td>No</td>
<td>16 (30.8)</td>
<td>19 (36.5)</td>
<td>30 (66.7)</td>
</tr>
<tr>
<td>Lack of support</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (38.5)</td>
<td>5 (38.5)</td>
<td>11 (91.7)</td>
</tr>
<tr>
<td>No</td>
<td>32 (37.7)</td>
<td>30 (35.3)</td>
<td>51 (68.9)</td>
</tr>
</tbody>
</table>

* The percentages reflect the number of people who responded to each item, which varied slightly due to a few missing data points

**P < .05
Generalist physicians may be particularly suited to treat opioid dependence, given their framework of treating the whole patient.

With increasing opioid abuse and addiction in the United States and limited access to pharmacologic treatment for opioid dependence, developing new mechanisms for delivering opioid addiction treatment is crucial. The ability to offer treatment with buprenorphine in the primary care setting has the potential to significantly improve both addiction treatment and overall health care for substance users. The majority of Bronx physicians in this study were aware of buprenorphine and would be willing to prescribe it with proper training and support. To develop effective programs to treat opioid addiction in the primary care setting, barriers and training and support needs identified by primary care physicians must be addressed for physicians to accept and incorporate opioid addiction treatment with buprenorphine into the primary care setting.

Acknowledgment: Portions of this manuscript were presented at the Third International Conference on Urban Health in Boston, October 2004.

Corresponding Author: Address correspondence to Dr. Cunningham, Montefiore Medical Center/Albert Einstein College of Medicine, Medicine, Family, and Social Medicine, 111 E. 210th Street, Bronx, NY 10467. 718-944-3860. Fax: 718-944-3841. ccunning@montefiore.org.

REFERENCES